Triorganotin (IV) carboxylates as potential anticancer agents: Their synthesis, physiochemical characterization, and cytotoxic activity against HeLa and MCF‐7 cancer cells. (27th January 2021)
- Record Type:
- Journal Article
- Title:
- Triorganotin (IV) carboxylates as potential anticancer agents: Their synthesis, physiochemical characterization, and cytotoxic activity against HeLa and MCF‐7 cancer cells. (27th January 2021)
- Main Title:
- Triorganotin (IV) carboxylates as potential anticancer agents: Their synthesis, physiochemical characterization, and cytotoxic activity against HeLa and MCF‐7 cancer cells
- Authors:
- Uddin, Noor
Rashid, Faisal
Haider, Ali
Tirmizi, Syed Ahmed
Raheel, Ahmad
Imran, Muhammad
Zaib, Sumera
Diaconescu, Paula L.
Iqbal, Jamshed
Ali, Saqib - Abstract:
- Abstract : Three triorganotin (IV) cyclopentane carboxylates were synthesized and structurally characterized by in solid state by Fourier‐transform infrared spectroscopy and single crystal diffraction, and in solution by NMR ( 1 H, 13 C, and 119 Sn) spectroscopy. The complexes were tested for their anticancer activity against MCF‐7 and HeLa cells along with normal BHK‐21 cells. As revealed by MTT assay, complex 2 was identified as the most potent derivative with an IC50 value of 2.59 and 0.051 μM against HeLa and MCF‐7 cells, respectively. The results were compared with cisplatin as reference drug. Fluorescent microscopic studies using 4′, 6‐diamidino‐2‐phenylindole (DAPI) and propidium iodide (PI) staining confirmed the occurrence of apoptosis in HeLa cells treated with the most active complex 2 . The complex 2 also triggered the release of lactate dehydrogenase (LDH) in treated HeLa and MCF‐7 cells whereas a luminescence assay displayed a remarkable increase in the activity of caspase‐9 and ‐3. Moreover, flow cytometric results revealed that complex 2 caused G0/G1 arrest in the treated HeLa cells. The complexes were further screened for DNA binding studies through UV‐vis spectroscopy and cyclic voltammetry. The high activity of complex 2 was attributed to its higher Lewis acidity as indicated by natural bond orbital (NBO) analysis. Theoretical modelling and molecular docking studies were also conducted to study the reactivity of complexes against VEGFR 2 Kinase . AbstractAbstract : Three triorganotin (IV) cyclopentane carboxylates were synthesized and structurally characterized by in solid state by Fourier‐transform infrared spectroscopy and single crystal diffraction, and in solution by NMR ( 1 H, 13 C, and 119 Sn) spectroscopy. The complexes were tested for their anticancer activity against MCF‐7 and HeLa cells along with normal BHK‐21 cells. As revealed by MTT assay, complex 2 was identified as the most potent derivative with an IC50 value of 2.59 and 0.051 μM against HeLa and MCF‐7 cells, respectively. The results were compared with cisplatin as reference drug. Fluorescent microscopic studies using 4′, 6‐diamidino‐2‐phenylindole (DAPI) and propidium iodide (PI) staining confirmed the occurrence of apoptosis in HeLa cells treated with the most active complex 2 . The complex 2 also triggered the release of lactate dehydrogenase (LDH) in treated HeLa and MCF‐7 cells whereas a luminescence assay displayed a remarkable increase in the activity of caspase‐9 and ‐3. Moreover, flow cytometric results revealed that complex 2 caused G0/G1 arrest in the treated HeLa cells. The complexes were further screened for DNA binding studies through UV‐vis spectroscopy and cyclic voltammetry. The high activity of complex 2 was attributed to its higher Lewis acidity as indicated by natural bond orbital (NBO) analysis. Theoretical modelling and molecular docking studies were also conducted to study the reactivity of complexes against VEGFR 2 Kinase . Abstract : Three new triorganotin (IV) carboxylates are synthesized and physiochemically characterized. The complexes are then tested for their anticancer activity against MCF‐7 and HeLa cells along with normal BHK‐21 cells and screened for DNA binding studies. The biological results have been supported by theoretical modelling and molecular docking studies. … (more)
- Is Part Of:
- Applied organometallic chemistry. Volume 35:Number 4(2021)
- Journal:
- Applied organometallic chemistry
- Issue:
- Volume 35:Number 4(2021)
- Issue Display:
- Volume 35, Issue 4 (2021)
- Year:
- 2021
- Volume:
- 35
- Issue:
- 4
- Issue Sort Value:
- 2021-0035-0004-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2021-01-27
- Subjects:
- anticancer studies -- DFT -- DNA binding studies -- docking -- triorganotin (IV) complexes
Organometallic chemistry -- Periodicals
Organometallic compounds -- Periodicals
547.05 - Journal URLs:
- http://www3.interscience.wiley.com/cgi-bin/jhome/109566206 ↗
http://www3.interscience.wiley.com/cgi-bin/jhome/2676 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/aoc.6165 ↗
- Languages:
- English
- ISSNs:
- 0268-2605
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1576.270000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 16167.xml